Former X CEO Linda Yaccarino lands new gig at digital health firm focused on weight loss drugs

Former X CEO Linda Yaccarino landed a new gig to head a digital health startup on Tuesday – just weeks after she abruptly stepped down from the helm of Elon Musk’s social media site.

Yaccarino, 61, will take over as CEO of Miami-based eMed Population Health, which provides support and resources for patients on Ozempic and other popular GLP-1 drugs used to treat obesity and diabetes, the company announced.

EMed cited the advertising veteran’s “undeniable ability to negotiate new partnerships” as a key factor as it looks to secure more deals with employers and government agencies.

“The healthcare industry has been disrupted by technology, but not yet completely transformed by it,” Yaccarino said in a statement.

“There is an opportunity to combine technology, lifestyle, and data in a new powerful way through the digital channels that impact consumers directly in ways that have never been done before,” she added.

Yaccarino resigned from X last month after two chaotic years working alongside Musk, who faced intense scrutiny over his work with President Trump’s Department of Government Efficiency.

Her exit was announced just one day after a glitch caused X’s Grok chatbot to spew antisemitic views, including referred to itself as “MechaHitler.”

However, a source close to the situation told The Post at the time that Yaccarino’s departure was already in the works and was unrelated to that incident.

“She got advertisers back and made it profitable again,” the source said. “(She) felt it was time to move on.”

The former NBCUniversial advertising executive joined X in 2023, shortly after Musk bought the site formerly known as Twitter, and was tasked with mending fences with major corporate advertisers stemming from the mogul’s overhaul of the platform.

Under Yaccarino’s leadership, X filed a federal antitrust lawsuit targeting the World Federation of Advertisers and a shadowy ad cabal known as the “Global Alliance for Responsible Media initiative,” or GARM, as part of a broader push for holding “brand safety” firms accountable for alleged censorship.

She will now take her talents to eMed, which was founded in 2020. The Miami-based company touts a range of services on its website, including “at-home diagnostics, proctor-led screenings, physician-guided prescribing,” according to a press release.

It also claims it can help reduce the cost of a weight-loss program by up to 50% for patients.